Webinar: Understanding Immunoglobulins – IVIg and SCIg Replacement Therapy

Join us for our next educational webinar aimed at understanding immunoglobulin therapy, and why it may be an important part of treatment for patients living with lymphoma to prevent infections and support the immune system.

The webinar will provide an overview of how immunoglobulin therapy works as a supportive treatment, how it is given including intravenous (IVIg) and subcutaneous (SCIg) options; and how patients can access this treatment – followed by a short Q and A with our guest presenter.

Event Details

Date: Wednesday 26th August 2026
Time: 4:00pm to 5:00pm (NSW/VIC/QLD/ACT/TAS)
3:30pm to 4:30pm (SA/NT)
2:00pm to 3:00pm (WA)
Location: Online via Zoom – Link sent on registration
Cost: Free – Registration Required

Guest Presenter

Leanne Hollis is a Clinical Specialist and Registered Nurse with extensive experience in specialist nursing and patient care. She currently works with Neomedix Systems, where she supports healthcare professionals, patients, and clinical staff through education and training in Subcutaneous Immunoglobulin (SCIg) Therapy across Australia and New Zealand.

Throughout her nursing career, Leanne has developed broad expertise in haematology, stem cell. transplantation, apheresis, and transfusion management, having worked as a Clinical Nurse Consultant across these highly specialised areas.

She is passionate about educating and supporting nurses to build their knowledge, skills, and confidence in delivering immunoglobulin therapies, thereby empowering patients to understand and confidently manage their treatment options.

Leanne is committed to improving patient outcomes through practical education, collaborative care, and ongoing support.

If you would like to submit any questions prior to the webinar, please email them through to nurse@lymphoma.org.au or call our Nurse Support Line on 1800 953 081
 

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Wednesday 26th of August 2026
Time: 4:00pm AEST - 5:00pm AEST

Support and information

Contact Lymphoma Australia Today!

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.